HHSO100201700016C↗
Regeneron Pharmaceuticals Inc received this contract from Barda - Aspr / Daappo / Barda Dcma, Office of Assistant Secretary for Preparedness and Response: $280.50M obligated so far for health r&d services; health care services; experimental development. It runs to 2031-09-29.
Key facts · data as of Oct 21, 2026
- Recipient
- Regeneron Pharmaceuticals Inc
- Awarding agency
- Office of Assistant Secretary for Preparedness and Response (Department of Health and Human Services)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Obligated to date
- $280.50M
- Potential value
- $1.04B
- Ends
- 2031-09-29
Source: USAspending.gov prime award records (obligations: money committed, not outlays), data as of Oct 21, 2026.
Cite this page: SpendQuery, Award HHSO100201700016C, data as of Oct 21, 2026, https://spendquery.com/award?id=CONT_AWD_HHSO100201700016C_7505_-NONE-_-NONE-
Regeneron Pharmaceuticals Inc: all federal awards · Department of Health and Human Services: spending · Barda - Aspr / Daappo / Barda Dcma: what it buys
IGF::OT::IGF
What it is
- Product or service
- Health R&D Services; Health Care Services; Experimental Development (PSC AN13)
- Industry
- Research and Development in Biotechnology (NAICS 541711)
- Contracting office
- Barda - Aspr / Daappo / Barda Dcma (75A501)
- Competition
- Full and open competition · 2 offers received
- Pricing
- Cost plus fixed fee
- How it was bought
- Standalone contract
- Solicitation
- 17100SOL00014
- Where the work is
- Westchester, NY · district NY-17
Obligations by fiscal year
SpendQuery holds FY2023 on; earlier years are on USAspending.gov.
Subcontractors: where the money went next
No subawards reported for this award. Primes report subawards of $30,000 or more; many awards have none.
Every action
6 actions since 2022-12-14. Each is a modification or amendment with the money it added or took back.
| Date | Modification | Kind | Amount | What the agency wrote |
|---|---|---|---|---|
| 2026-09-25 | P00018 | Option exercised | $277.82M | INMAZEB EBOLA THERAPEUTICS |
| 2026-07-30 | P00017 | Change order | $2.68M | INMAZEB EBOLA THERAPEUTICS |
| 2025-08-06 | P00016 | Change order | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.4 AND F.4 |
| 2024-12-06 | P00015 | Change order | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.1., ARTICLE C.1., ARTICLE F.4, , ARTICLE G.4. AND THE STATEMENT OF WORK. |
| 2023-11-07 | P00014 | Administrative change | $0 | NO COST MOD TO REVISE THE CONTRACT SECTIONS: ARTICLE B.2.2., B.4.Q., ARTICLE C.1., ARTICLE F.4, AND THE STATEMENT OF WORK. ADD ARTICLE B.4.R., ARTICLE H.31., AND FAR CLAUSE 52.204-27. |
| 2022-12-14 | P00013 | Change order | $0 | EBOLA THERAPEUTICS |
Source: USAspending.gov prime award transactions and FSRS subaward reports, as loaded by SpendQuery (data as of 2026-10-21). Amounts are obligations (money committed), not outlays. The official record on USAspending.gov ↗